Sodium Glucose Cotransporter 2 Inhibitor As a Promising Therapy for Congestive Kidney Injury

Overview

Journal Hypertens Res

Specialty Cardiology & Vascular Diseases

Date 2023 Nov 24

PMID 38001167

Authors

Kotaro Haruhara

Eisuke Kubo

Affiliations

Soon will be listed here.

References

Schefold J, Filippatos G, Hasenfuss G, Anker S, von Haehling S . Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016; 12(10):610-23. DOI: 10.1038/nrneph.2016.113. View

Damman K, Navis G, Voors A, Asselbergs F, Smilde T, Cleland J . Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007; 13(8):599-608. DOI: 10.1016/j.cardfail.2007.04.008. View

Ljungman S, LARAGH J, Cody R . Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990; 39 Suppl 4:10-21; discussion 22-4. DOI: 10.2165/00003495-199000394-00004. View

Mullens W, Abrahams Z, Francis G, Sokos G, Taylor D, Starling R . Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009; 53(7):589-596. PMC: 2856960. DOI: 10.1016/j.jacc.2008.05.068. View

Anand I . Cardiorenal syndrome: a cardiologist's perspective of pathophysiology. Clin J Am Soc Nephrol. 2013; 8(10):1800-7. PMC: 3789344. DOI: 10.2215/CJN.04090413. View

Afsar B, Ortiz A, Covic A, Solak Y, Goldsmith D, Kanbay M . Focus on renal congestion in heart failure. Clin Kidney J. 2016; 9(1):39-47. PMC: 4720202. DOI: 10.1093/ckj/sfv124. View

Shimada S, Hirose T, Takahashi C, Sato E, Kinugasa S, Ohsaki Y . Pathophysiological and molecular mechanisms involved in renal congestion in a novel rat model. Sci Rep. 2018; 8(1):16808. PMC: 6235885. DOI: 10.1038/s41598-018-35162-4. View

van Ham W, Kessler E, Oerlemans M, Handoko M, Sluijter J, van Veen T . Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models. JACC Basic Transl Sci. 2022; 7(8):844-857. PMC: 9436760. DOI: 10.1016/j.jacbts.2021.12.009. View

Masuda T, Nagata D . Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease. Hypertens Res. 2023; 46(5):1195-1201. DOI: 10.1038/s41440-023-01220-2. View

10.

Zhuo M, Paik J, Wexler D, Bonventre J, Kim S, Patorno E . SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. Am J Kidney Dis. 2021; 79(6):858-867.e1. PMC: 9079190. DOI: 10.1053/j.ajkd.2021.09.015. View

11.

Chung M, Hung P, Hsiao P, Wu L, Chang C, Hsiao K . Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan. JAMA Netw Open. 2023; 6(2):e230453. PMC: 9947724. DOI: 10.1001/jamanetworkopen.2023.0453. View

12.

Voors A, Angermann C, Teerlink J, Collins S, Kosiborod M, Biegus J . The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022; 28(3):568-574. PMC: 8938265. DOI: 10.1038/s41591-021-01659-1. View